Surgery Partners ends acquisition talks with Bain Capital

Surgery Partners (SGRY) announced that discussions with Bain Capital regarding the acquisition of outstanding shares have ended without an agreement, as the Special Committee believes the company's prospects as an independent entity are more valuable; the company reaffirmed its full-year 2025 guidance, projecting revenues of $3.30B-$3.45B and Adjusted EBITDA of $555M-$565M, aligning with analysts' "Buy" consensus and a potential 45% upside from current levels. Despite the unsuccessful acquisition talks, Bain Capital expressed optimism about Surgery Partners' business and growth strategy.

Analysis

Surgery Partners, Inc. (NASDAQ:SGRY), with a market capitalization of approximately $3 billion, has ceased acquisition discussions with Bain Capital Private Equity after its Special Committee determined that the company's prospects as an independent entity exceed Bain's non-binding offer. This confidence is supported by a reaffirmed full-year 2025 guidance, projecting revenues between $3.30 billion and $3.45 billion and Adjusted EBITDA between $555 million and $565 million, figures bolstered by strong first-quarter performance and a notable 13.5% revenue growth in the last twelve months. InvestingPro data indicates a "GOOD" overall financial health score for Surgery Partners, with an expectation of net income improvement this year. Despite the unsuccessful transaction, Bain Capital expressed continued optimism about Surgery Partners' business, leadership, and growth strategy within the high-growth outpatient surgical care market. Analyst sentiment is generally positive, with a consensus "Buy" recommendation and an indicated potential upside of 45% from current trading levels. Specific analyst ratings include a Buy from UBS with a $34.00 price target, an Overweight from Cantor Fitzgerald citing stable trends and potential undervaluation, and a Sector Weight from KeyBanc Capital Markets, which noted modest Q1 EBITDA outperformance and robust same-store revenue growth expected to normalize. Surgery Partners plans to further detail its strategy and outlook at an Investor Day in the second half of 2025.

Key Decisions for Investors

• Investors should consider the Special Committee's decision to remain independent, backed by strong 2025 guidance and 13.5% LTM revenue growth, as a signal of management's conviction in standalone value creation potential.
• Monitor the company's progress towards its reaffirmed 2025 revenue and Adjusted EBITDA targets, and anticipate further strategic articulation at the upcoming Investor Day in H2 2025, which could serve as a significant catalyst.
• Evaluate the potential 45% upside suggested by analyst consensus against the backdrop of the company's performance in the high-growth outpatient surgical market, while noting KeyBanc's expectation for the normalization of same-store revenue growth through 2025.